BEAM - Why Beam Therapeutics Stock Rocketed Higher This Week
Shares of the clinical-stage base-editing company Beam Therapeutics (NASDAQ: BEAM) stormed higher through the first four days of trading this week. Specifically, the biotech's stock gained a healthy 16.6%, according to data from S&P Global Market Intelligence .
Oddly enough, this double-digit move wasn't accompanied by a material news event. Beam's sizable uptick seems to simply be a rebound following last week's 23% drop in its share price.
Clinical-stage biotech stocks have been extremely volatile this year, thanks to rising interest rates, geopolitical turmoil, and investors' general aversion to risk right now. Consequently, promising next-generation gene-editing companies like Beam have seen wild swings in their shares all year long.
For further details see:
Why Beam Therapeutics Stock Rocketed Higher This Week